Purdue Pharma headquarters in Stamford, Connecticut. Photo: Drew Angerer/Getty Images

New court records reviewed by Stat show how Richard Sackler, a former executive at Purdue Pharma, guided the company's promotional strategy for the launch of its opioid pain medication OxyContin.

Why it matters: Sackler's family founded and controls Purdue Pharma. The company in 2007 pleaded guilty to a felony related to falsely promoting OxyContin as less addictive and not as likely to produce tolerance or symptoms of withdrawal than other pain medications, even though the drugs is twice as strong as morphine. More than 218,000 Americans have died from overdoses of all prescription opioids.

Details: Sackler learned in 1997 that one of the nation’s largest pharmacy benefit managers at the time, Merck Medco, was cautioning doctors that Purdue's new drug could be abused by chronic pain patients. He proposed in emails that Purdue executives give a “convincing presentation” to physicians to rebutt Merck Medco's guidance.

  • The presentations would claim that controlled-release pills like OxyContin are “less prone to addiction potential, abuse or diversion” than other opioid pain medications, according to the court documents reviewed by Stat.
  • Sackler also called for a media campaign to counter Merck Medco's concerns, saying in emails that the company "may need to start a campaign to focus attention on the untreated patient in severe pain who is mobilized and given his life back by our products.”
  • Sackler praised Perdue executives for building relationships with doctors and medical organizations that create treatment guidelines for pain patients — a key component to Purdue’s marketing strategy.

The big picture: Two dozen states and Washington, D.C., are fighting a tentative national settlement that the Sackler family and Purdue Pharma have reached with 24 other states and about 2,000 cities, counties and Native American tribes.

  • Under the proposal, the Sacklers would pay plaintiffs $3 billion, sell another family-owned drug company that markets opioids globally and give up control of Purdue. Plaintiffs would receive revenues from OxyContin and other products.
  • In total, the Sacklers received $12 billion to $13 billion in profits from Purdue.

Go deeper:

Go deeper

Updated 6 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Politics: The swing states where the pandemic is raging. Ex-FDA chief: Pence campaigning after COVID exposure puts others at risk — Mark Meadows: "We are not going to control the pandemic"
  2. Health: 13 states set single-day coronavirus case records last week — U.S. reports over 80,000 new cases for second consecutive day.
  3. Education: The dangerous instability of school re-openings.
  4. World: Australian city to exit one of world's longest lockdowns — In photos: Coronavirus restrictions grow across Europe
  5. Media: Fox News president and several hosts advised to quarantine after possible COVID-19 exposure
  6. Nonprofit: Rockefeller Foundation commits $1 billion for COVID-19 recovery
Dion Rabouin, author of Markets
2 hours ago - Economy & Business

Bond investors see brighter days

Illustration: Sarah Grillo/Axios

U.S. government bonds could breakout further after yields on the benchmark 10-year Treasury note ticked up to their highest since early June last week.

But, but, but: Strategists say this move is about an improving outlook for economic growth rather than just inflation.

Erica Pandey, author of @Work
4 hours ago - Economy & Business

The dangerous instability of school re-openings

Illustration: Eniola Odetunde/Axios

Schools across the country have flip-flopped between in-person and remote learning — and that instability is taking a toll on students' ability to learn and their mental health.

The big picture: While companies were able to set long timelines for their return, schools — under immense political and social strain — had to rush to figure out how to reopen. The cobbled-together approach has hurt students, parents and teachers alike.